ONCINo — Oncoinvent ASA Share Price
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- NOK1.94m
- -NOK67.57m
- NOK0.85m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.66 | ||
| Price to Tang. Book | 0.66 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 8.19 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -172.08% | ||
| Return on Equity | -88.81% | ||
| Operating Margin | -2133.19% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | NOKm | 0.6 | 0.77 | 0.39 | 0.35 | 0.85 | n/a | n/a | -37.51% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bergenbio ASA is a Norway-based clinical-stage biopharmaceutical company focused on developing drugs for aggressive diseases including cancer and severe respiratory infections. The Company's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) which is a tyrosine kinase target that mediates aggressive disease. Under normal healthy physiological conditions, there is low expression of AXL. However, in aggressive diseases, such as cancer and severe respiratory infections, AXL signaling is upregulated in response to hypoxia, inflammation, cellular stress and drug treatment. The Company's flagship product is BGB324, is a selective, potent and orally bio-available small molecule AXL inhibitor in Phase II clinical trials in cancer indications and COVID-19. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK.
Directors
- Anders Tullgren CHM (61)
- Rune Skeie CFO (44)
- Endre Kjaerland OTH
- Julia Schoelermann OTH
- Dominic Smethurst OTH
- Victoria Wills OTH
- Sveinung Hole DRC
- Martin Olin DRC (52)
- Debra Barker NED (58)
- Grunde Eriksen NED
- Pamela Trail NED
- Stener Kvinnsland NID
- Last Annual
- December 31st, 2024
- Last Interim
- June 30th, 2025
- Incorporated
- January 31st, 2008
- Public Since
- April 7th, 2017
- No. of Employees
- 7
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 39,087,116
- Address
- Nygardsgaten 114, BERGEN, 5008
- Web
- https://www.bergenbio.com/
- Phone
- +47 55961159
- Auditors
- Ernst & Young AS
Upcoming Events for ONCINo
Q3 2025 Bergenbio ASA Earnings Release
Q4 2025 Bergenbio ASA Earnings Release
Similar to ONCINo
2cureX AB
OMX Nordic Exchange Stockholm
Acousort AB
OMX Nordic Exchange Stockholm
Active Biotech AB publ
OMX Nordic Exchange Stockholm
Alligator Bioscience AB
OMX Nordic Exchange Stockholm
AlzeCure Pharma AB
OMX Nordic Exchange Stockholm
FAQ
What is the Oncoinvent ASA share price?
As of Today at 21:27 UTC, shares in Oncoinvent ASA are trading at NOK10.00. This share price information is delayed by 15 minutes.
How has the Oncoinvent ASA share price performed this year?
Shares in Oncoinvent ASA last closed at NOK10.00 and the price had moved by -87.16% over the past 365 days. In terms of relative price strength the Oncoinvent ASA share price has underperformed the FTSE Global All Cap Index by -88.16% over the past year.
What are the analyst and broker recommendations for Oncoinvent ASA?
The overall consensus recommendation for Oncoinvent ASA is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Oncoinvent ASA dividend yield?
Oncoinvent ASA does not currently pay a dividend.
Does Oncoinvent ASA pay a dividend?
Oncoinvent ASA does not currently pay a dividend.
When does Oncoinvent ASA next pay dividends?
Oncoinvent ASA does not currently pay a dividend.
How do I buy Oncoinvent ASA shares?
To buy shares in Oncoinvent ASA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Oncoinvent ASA?
As of the previous close price of NOK10.00, shares in Oncoinvent ASA had a market capitalisation of NOK44.25m.
Where are Oncoinvent ASA shares listed?
Here are the trading details for Oncoinvent ASA:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: BGBIOo
What kind of share is Oncoinvent ASA?
Based on an overall assessment of its quality, value and momentum Oncoinvent ASA is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Oncoinvent ASA share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Oncoinvent ASA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Oncoinvent ASA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -88.52%.
As of the last closing price of NOK10.00, shares in Oncoinvent ASA were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Oncoinvent ASA PE Ratio?
The Oncoinvent ASA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at NOK10.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Oncoinvent ASA?
Oncoinvent ASA's management team is headed by:
- Anders Tullgren - CHM
- Rune Skeie - CFO
- Endre Kjaerland - OTH
- Julia Schoelermann - OTH
- Dominic Smethurst - OTH
- Victoria Wills - OTH
- Sveinung Hole - DRC
- Martin Olin - DRC
- Debra Barker - NED
- Grunde Eriksen - NED
- Pamela Trail - NED
- Stener Kvinnsland - NID